- Home
- LVO vs KLRS Comparison
LVO vs KLRS Comparison
Compare LVO & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LVO | KLRS |
|---|---|---|
| Founded | 2009 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.2M | 46.0M |
| IPO Year | 2010 | N/A |
Fundamental Metrics
Financial Performance| Metric | LVO | KLRS |
|---|---|---|
| Price | $5.45 | $10.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $13.00 | ★ $20.67 |
| AVG Volume (30 Days) | ★ 77.3K | 54.9K |
| Earning Date | 05-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 78.57 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $114,405,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $28.61 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.43 | $2.14 |
| 52 Week High | $6.04 | $11.90 |
Technical Indicators
Market Signals| Indicator | LVO | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 58.14 | 55.24 |
| Support Level | $3.95 | $8.08 |
| Resistance Level | $5.47 | $10.36 |
| Average True Range (ATR) | 0.55 | 1.11 |
| MACD | 0.04 | 0.10 |
| Stochastic Oscillator | 70.06 | 71.61 |
Price Performance
Historical ComparisonAbout LVO LiveOne Inc.
LiveOne Inc, formerly LiveXLive Media Inc is a premium internet network devoted to live music and music-related video content. The company has been building an online destination for music fans to enjoy live performances from music venues and music festivals around the world, such as Rock in Rio, Outside Lands Music and Arts Festival, and Hangout Music Festival, as well as original content, artist exclusives, and industry interviews. The Company operates mainly through three segments, PodcastOne, Slacker, and Media Group, with a majority of its revenue derived from the Slacker segment.
About KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.